Research Paper Volume 13, Issue 17 pp 21671—21699

Figure 7. Association of DNA methylation of TfR1 with clinicopathological parameters of BC patients. The DNA methylation of TfR1 was investigated in (A) BC patients (n = 793) and normal individuals (n = 97); female (n = 783) and male (n = 9) BC patients; patients with different BC subtypes (normal individuals, n = 97; HER2-positive, n = 17; luminal, n = 393; and TNBC, n = 84); patients with different stages of BC (normal individuals, n = 97; stage 1, n = 127; stage 2, n = 442; stage 3, n = 200; and stage 4, n = 11); patients with different nodal metastasis statuses (normal individuals, n = 97; N0, n = 233; N1, n = 242; N2, n = 95; and N3, n = 20); and patients with different ages (normal individuals, n = 97; 21–40 years, n = 73; 41–60 years, n = 374; 61–80 years, n = 306; and 81–100 years, n = 37). (B) Methylation levels of TfR1 in BC through the SurvivalMeth database. (C) The heat map of DNA methylation of TfR1 in BC. ^*< 0.05, ^**< 0.01, ^***< 0.001.